Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 10 | 2025 | 285 | 1.500 |
Why?
|
| Free Tissue Flaps | 7 | 2024 | 63 | 1.330 |
Why?
|
| Cochlear Implants | 1 | 2022 | 67 | 0.720 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2022 | 78 | 0.710 |
Why?
|
| Cochlear Implantation | 1 | 2022 | 81 | 0.700 |
Why?
|
| Speech Perception | 1 | 2022 | 98 | 0.700 |
Why?
|
| Mandibular Reconstruction | 3 | 2024 | 15 | 0.630 |
Why?
|
| Retrospective Studies | 25 | 2025 | 6610 | 0.580 |
Why?
|
| Thyroid Neoplasms | 2 | 2022 | 113 | 0.410 |
Why?
|
| Treatment Outcome | 12 | 2024 | 5456 | 0.410 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2024 | 630 | 0.370 |
Why?
|
| Sinusitis | 2 | 2022 | 42 | 0.350 |
Why?
|
| Neck Dissection | 2 | 2021 | 29 | 0.350 |
Why?
|
| Middle Aged | 19 | 2025 | 13028 | 0.340 |
Why?
|
| Length of Stay | 2 | 2024 | 666 | 0.340 |
Why?
|
| Parathyroidectomy | 2 | 2021 | 46 | 0.330 |
Why?
|
| Stapes Surgery | 2 | 2020 | 24 | 0.320 |
Why?
|
| Humans | 34 | 2025 | 52114 | 0.300 |
Why?
|
| Male | 22 | 2025 | 26652 | 0.300 |
Why?
|
| Tympanoplasty | 2 | 2020 | 57 | 0.300 |
Why?
|
| Aged | 15 | 2025 | 10142 | 0.300 |
Why?
|
| Meniere Disease | 1 | 2008 | 21 | 0.290 |
Why?
|
| Adult | 14 | 2025 | 14095 | 0.280 |
Why?
|
| Otolaryngology | 1 | 2008 | 61 | 0.280 |
Why?
|
| Incidental Findings | 1 | 2007 | 41 | 0.270 |
Why?
|
| Time-to-Treatment | 2 | 2025 | 77 | 0.260 |
Why?
|
| Female | 21 | 2025 | 28055 | 0.250 |
Why?
|
| Thyroidectomy | 3 | 2021 | 61 | 0.250 |
Why?
|
| Carcinoma | 1 | 2007 | 136 | 0.250 |
Why?
|
| Osteoradionecrosis | 1 | 2024 | 6 | 0.230 |
Why?
|
| Mandibular Diseases | 1 | 2024 | 11 | 0.220 |
Why?
|
| Postoperative Complications | 5 | 2024 | 1071 | 0.220 |
Why?
|
| Mandible | 1 | 2024 | 25 | 0.220 |
Why?
|
| Skull | 1 | 2024 | 77 | 0.210 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2024 | 19 | 0.210 |
Why?
|
| Scalp | 1 | 2024 | 43 | 0.210 |
Why?
|
| Physical Examination | 1 | 2024 | 98 | 0.210 |
Why?
|
| Deglutition | 1 | 2024 | 44 | 0.210 |
Why?
|
| Operative Time | 1 | 2023 | 77 | 0.200 |
Why?
|
| Scapula | 1 | 2023 | 16 | 0.200 |
Why?
|
| Enteral Nutrition | 1 | 2024 | 153 | 0.200 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2023 | 54 | 0.200 |
Why?
|
| Deglutition Disorders | 1 | 2024 | 76 | 0.200 |
Why?
|
| Caregivers | 1 | 2025 | 236 | 0.200 |
Why?
|
| Parathyroid Hormone | 2 | 2021 | 149 | 0.190 |
Why?
|
| Reoperation | 2 | 2021 | 463 | 0.190 |
Why?
|
| Tramadol | 1 | 2022 | 30 | 0.190 |
Why?
|
| Surgical Flaps | 1 | 2023 | 110 | 0.190 |
Why?
|
| Sensitivity and Specificity | 1 | 2024 | 871 | 0.190 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 1148 | 0.180 |
Why?
|
| Hearing Loss, Conductive | 2 | 2019 | 55 | 0.180 |
Why?
|
| Intraoperative Care | 1 | 2021 | 51 | 0.180 |
Why?
|
| Recurrent Laryngeal Nerve Injuries | 1 | 2021 | 6 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 330 | 0.180 |
Why?
|
| Chylothorax | 1 | 2021 | 16 | 0.170 |
Why?
|
| Hypotension | 1 | 2021 | 62 | 0.170 |
Why?
|
| Vasoconstrictor Agents | 1 | 2021 | 80 | 0.170 |
Why?
|
| Robotics | 1 | 2021 | 43 | 0.170 |
Why?
|
| Paranasal Sinuses | 1 | 2020 | 15 | 0.170 |
Why?
|
| Health Services Accessibility | 1 | 2025 | 438 | 0.170 |
Why?
|
| Rhinitis | 1 | 2020 | 28 | 0.170 |
Why?
|
| Intraoperative Complications | 1 | 2021 | 113 | 0.170 |
Why?
|
| Morbidity | 1 | 2021 | 140 | 0.170 |
Why?
|
| Chlorides | 1 | 2020 | 43 | 0.170 |
Why?
|
| Otosclerosis | 1 | 2020 | 10 | 0.170 |
Why?
|
| Tympanic Membrane Perforation | 1 | 2020 | 20 | 0.160 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2020 | 34 | 0.160 |
Why?
|
| Ossicular Prosthesis | 1 | 2020 | 19 | 0.160 |
Why?
|
| Adenoma | 1 | 2021 | 112 | 0.160 |
Why?
|
| Acetaminophen | 1 | 2022 | 277 | 0.160 |
Why?
|
| Skin Neoplasms | 1 | 2024 | 499 | 0.150 |
Why?
|
| Malleus | 1 | 2019 | 11 | 0.150 |
Why?
|
| Calcium | 1 | 2020 | 372 | 0.150 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 316 | 0.140 |
Why?
|
| Aged, 80 and over | 5 | 2024 | 3382 | 0.140 |
Why?
|
| Heart Defects, Congenital | 1 | 2023 | 611 | 0.130 |
Why?
|
| Neoplasms | 1 | 2025 | 1288 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2020 | 433 | 0.120 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2025 | 63 | 0.110 |
Why?
|
| Fibula | 2 | 2024 | 23 | 0.110 |
Why?
|
| Radiopharmaceuticals | 2 | 2021 | 199 | 0.100 |
Why?
|
| Breast Neoplasms | 1 | 2022 | 1199 | 0.100 |
Why?
|
| Audiometry | 2 | 2020 | 35 | 0.080 |
Why?
|
| Tympanic Membrane | 2 | 2020 | 37 | 0.080 |
Why?
|
| Postoperative Period | 2 | 2020 | 170 | 0.080 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2007 | 11 | 0.070 |
Why?
|
| Whole Body Imaging | 1 | 2007 | 25 | 0.070 |
Why?
|
| Equipment Design | 1 | 2008 | 290 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2024 | 2424 | 0.070 |
Why?
|
| Prognosis | 2 | 2024 | 2093 | 0.060 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2007 | 181 | 0.060 |
Why?
|
| Positron-Emission Tomography | 1 | 2007 | 297 | 0.060 |
Why?
|
| Erythrocyte Transfusion | 1 | 2024 | 51 | 0.050 |
Why?
|
| Incidence | 1 | 2007 | 1070 | 0.050 |
Why?
|
| Fluoroscopy | 1 | 2024 | 51 | 0.050 |
Why?
|
| Adolescent | 3 | 2020 | 6681 | 0.050 |
Why?
|
| Video Recording | 1 | 2024 | 78 | 0.050 |
Why?
|
| Critical Pathways | 1 | 2023 | 36 | 0.050 |
Why?
|
| Social Support | 1 | 2025 | 268 | 0.050 |
Why?
|
| Child | 3 | 2020 | 7147 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2024 | 129 | 0.050 |
Why?
|
| Forearm | 1 | 2023 | 31 | 0.050 |
Why?
|
| Ambulatory Care Facilities | 1 | 2023 | 124 | 0.050 |
Why?
|
| Ibuprofen | 1 | 2022 | 24 | 0.050 |
Why?
|
| Thyroid Gland | 1 | 2022 | 77 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2024 | 634 | 0.050 |
Why?
|
| Albumins | 1 | 2022 | 29 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2002 | 47 | 0.050 |
Why?
|
| Ambulatory Care | 1 | 2023 | 239 | 0.050 |
Why?
|
| Neoplasm Staging | 1 | 2024 | 766 | 0.050 |
Why?
|
| Recurrent Laryngeal Nerve | 1 | 2021 | 12 | 0.050 |
Why?
|
| Laryngeal Nerves | 1 | 2021 | 15 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2024 | 939 | 0.040 |
Why?
|
| Pain, Postoperative | 1 | 2022 | 169 | 0.040 |
Why?
|
| Glossectomy | 1 | 2021 | 5 | 0.040 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2021 | 17 | 0.040 |
Why?
|
| Head | 1 | 2021 | 70 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2020 | 4001 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2021 | 218 | 0.040 |
Why?
|
| Radionuclide Imaging | 1 | 2021 | 104 | 0.040 |
Why?
|
| Acute Disease | 1 | 2022 | 386 | 0.040 |
Why?
|
| Risk | 1 | 2022 | 312 | 0.040 |
Why?
|
| Neck | 1 | 2021 | 98 | 0.040 |
Why?
|
| Tongue | 1 | 2021 | 40 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2021 | 374 | 0.040 |
Why?
|
| Arteries | 1 | 2021 | 93 | 0.040 |
Why?
|
| Data Collection | 1 | 2022 | 286 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2002 | 238 | 0.040 |
Why?
|
| Stapes | 1 | 2020 | 12 | 0.040 |
Why?
|
| Self-Assessment | 1 | 2020 | 43 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2022 | 712 | 0.040 |
Why?
|
| Cartilage | 1 | 2020 | 47 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2002 | 242 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 1665 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 564 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 392 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 4307 | 0.040 |
Why?
|
| Endoscopy | 1 | 2020 | 123 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2023 | 1214 | 0.040 |
Why?
|
| Blood Glucose | 1 | 2022 | 475 | 0.040 |
Why?
|
| Arkansas | 1 | 2025 | 2016 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2022 | 1193 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 2282 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 396 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2020 | 585 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2022 | 1339 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2020 | 396 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2022 | 587 | 0.030 |
Why?
|
| Apoptosis | 1 | 2002 | 1117 | 0.030 |
Why?
|
| Risk Factors | 1 | 2024 | 3922 | 0.030 |
Why?
|
| Quality of Life | 1 | 2020 | 878 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2002 | 1214 | 0.030 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 2 | 0.010 |
Why?
|
| BH3 Interacting Domain Death Agonist Protein | 1 | 2002 | 14 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 20 | 0.010 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2002 | 30 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2002 | 86 | 0.010 |
Why?
|
| Caspases | 1 | 2002 | 102 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2002 | 128 | 0.010 |
Why?
|
| Ligands | 1 | 2002 | 206 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 445 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2002 | 588 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 596 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 316 | 0.010 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2002 | 324 | 0.010 |
Why?
|